New data from the open-label extension trial of the phase 2 RESCUE-ALS study (NCT04098406) for amyotrophic lateral sclerosis (ALS) suggest nanocrystalline gold (CNM-Au8; Clene Nanomedicine, Salt Lake City, UT) slows clinical decline. RESCUE-ALS is a phase 2 study that is not powered for statistical analysis of survival. Using the European Network for the Cure of […]

A novel treatment for amyotrophic lateral sclerosis (ALS) that targets brain cell energy production to promote remyelination showed signs of efficacy in a phase 2 trial, though it did not meet its primary endpoint, which was the change in the summated motor unit index (MUNIX) from baseline to week 36. The drug, CNM-Au8, is being developed by […]

Sigyn’s Jeremy Farrell is preparing to issue more shares even as some companies are shying away from tapping equity amid rising stock market volatility. Sigyn Therapeutic’s new CFO is betting the medical technology company can overcome stock market volatility to unlock a longer-term financing runway through a shelf registration and an uplisting to the Nasdaq exchange […]